文献速递免疫规划

CPA F联合ADU-S100鼻内免疫诱导效应CD4 T细胞应答并降低鼠衣原体阴道感染后的细菌负荷

Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum.
PubMed 文献 · Vaccine · 2024-11-12

研究在雌性小鼠中比较CPA F联合不同佐剂鼻内免疫的效果,发现CPA F加ADU-S100耐受良好,诱导以TNFα单独或联合IL-17A或IFNγ为特征的CD4 T细胞,显著减少鼠衣原体阴道攻击后的细菌排出并缩短感染持续时间,提示CDA可作为衣原体生殖道感染疫苗的黏膜佐剂。

要点

  • CPA F联合ADU-S100鼻内免疫在雌性小鼠中耐受良好。
  • 该方案诱导产生TNFα或联合IL-17A/IFNγ的CD4 T细胞。
  • 免疫后显著减少鼠衣原体阴道攻击后的细菌排出并缩短感染持续时间。

核心结论

  • 数据表明CDA有潜力作为抗衣原体生殖道感染疫苗的黏膜佐剂。

研究设计与样本

  • 在无细胞蛋白合成平台生产CPA F,联合TLR9激动剂CpG1826、合成环二AMP STING激动剂ADU-S100和/或角鲨烯水包油纳米乳AddaS03,对雌性小鼠进行鼻内免疫,并以鼠衣原体阴道攻击。

主要发现

  • CPA F联合ADU-S100鼻内免疫在雌性小鼠中耐受良好。
  • 该免疫诱导以TNFα单独产生或联合IL-17A或IFNγ为特征的CD4 T细胞。
  • 该免疫显著减少鼠衣原体阴道攻击后的细菌排出并缩短感染持续时间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chlamydia trachomatis (Ct) is the most common bacterial sexually transmitted infection globally, and a vaccine is urgently needed to stop transmission and disease. Chlamydial Protease Activity Factor (CPAF) is an immunoprevalent and immunodominant antigen for CD4 T cells and B cells, which makes it a strong vaccine candidate. Due to the tolerogenic nature of the female genital tract (FGT) and its lack of secondary lymphoid tissue, effective induction of protective cell-mediated immunity will likely require potent and safe mucosal adjuvants. To address this need, we produced CPAF in a cell-free protein synthesis platform and adjuvanted it with the TLR9-agonist CpG1826, a synthetic cyclic-di-AMP (CDA) STING (stimulator of interferon genes) agonist ADU-S100, and/or the squalene oil-in-water nanoemulsion, AddaS03. We determined that intranasal immunization with CPAF plus ADU-S100 was well tolerated in female mice, induced CD4 T cells characterized by TNFα production alone or in combination with IL-17 A or IFNγ, significantly reduced bacterial shedding, and shortened the duration of infection in mice intravaginally challenged with Chlamydia muridarum. These data demonstrate the potential for CDA as a mucosal adjuvant for vaccines against Chlamydia genital tract infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Poston TB, Girardi J, Kim M, et al. Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum. Vaccine. 2024. PMID: 39536454. doi:10.1016/j.vaccine.2024.126526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。